Publication: Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
Loading...
Institution Authors
Author
Panaccione, Remo
Colombel, Jean-Frederic
Travis, Simon P. L.
Bossuyt, Peter
Baert, Filip
Vanasek, Tomas
Danalioglu, Ahmet
Advisor
Program
Date
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Objective To evaluate the cost-effectiveness of an inflammatory biomarker and clinical symptom directed tight control strategy (TC) compared with symptom-based clinical management (CM) in patients with Crohn-s disease (CD) naive to immunosuppressants and biologics using a UK public payer perspective.
Description
Source
Keywords
Keywords
Citation
Panaccione R., Colombel J., Travis S. P. L. , Bossuyt P., Baert F., Vanasek T., Danalioglu A., Novacek G., Armuzzi A., Reinisch W., et al., -Tight control for Crohn-s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial-, GUT, cilt.69, ss.658-664, 2020